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The luteinizing hormone/chorionic gonadotropin receptor (LHCGR) is essential for fertility
in men and women. LHCGR binds luteinizing hormone (LH) as well as the highly homologous chorionic gonadotropin. Signaling from LHCGR is required for steroidogenesis
and gametogenesis in males and females and for sexual differentiation in the male.
The importance of LHCGR in reproductive physiology is underscored by the large number of naturally occurring inactivating and activating mutations in the receptor that result
in reproductive disorders. Consequently, several genetically modified mouse models
have been developed for the study of LHCGR function. They include targeted deletion of
LH and LHCGR that mimic inactivating mutations in hormone and receptor, expression
of a constitutively active mutant in LHCGR that mimics activating mutations associated
with familial male-limited precocious puberty and transgenic models of LH and hCG
overexpression. This review summarizes the salient findings from these models and their
utility in understanding the physiological and pathological consequences of loss and gain
of function in LHCGR signaling.
Keywords: luteinizing hormone receptor, gonadotropins, inactivating and activating mutations, genetic models,
knockout mice, knockin mice, transgenic mice

Introduction
The luteinizing hormone/chorionic gonadotropin receptor (LHCGR), together with the glycoprotein hormone receptors, follicle-stimulating hormone receptor (FSHR) and thyroid stimulating
hormone receptor (TSHR), belongs to the G protein-coupled receptor superfamily (1). LHCGR is
the target receptor for the pituitary-derived luteinizing hormone (LH) and the highly homologous
placental chorionic gonadotropin (CG). The fully processed human LHCGR is 675 amino acid residues long and is characterized by a large extracellular domain that is sufficient for hormone binding
(2). The LHCGR has 11 exons with the first 10 exons encoding the extracellular domain and exon
11 encoding the C-terminal tail of the hinge region of the extracellular domain, the transmembrane
helices with the connecting extra- and intracellular loops, and the cytoplasmic tail (1, 2). Functional
LHCGR is essential for sex differentiation in the fetus and reproductive function in the adult. During
fetal development in males, LHCGR present in the interstitial fetal Leydig cells of the testis binds to
placental CG to produce testosterone required for male sexual differentiation (3, 4). Postnatally, LH
stimulates LHCGR in the Leydig cells to produce testosterone required for development of puberty,
male secondary sexual characteristics, and spermatogenesis. Female fetal sex differentiation does not
require LH or steroid hormones. Postnatally, in females, LHCGR is present in the theca cells lining
the follicle, mature granulosa cells, stromal cells, and luteinized cells. LH activation of LHCGR in the
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theca cells stimulates androgen production, thereby providing
the substrate for conversion to estradiol by follicle-stimulating
hormone (FSH) induced aromatase in granulosa cells and triggering puberty (5). LHCGR activation is required for ovulation
and subsequent progesterone production by the corpus luteum
(6). The canonical signaling pathway mediated by LHCGR for
steroidogenesis is the Gαs/cAMP/protein kinase A pathway.
However, LHCGR can also activate additional pathways, including the Gαq/inositol phosphate/protein kinase C, protein kinase
B, and ERK1/2 pathways (6–10). In the testis, the ERK1/2 cascade
modulates androgen synthesis as well as proliferation/survival
of Leydig cells (11–15). In the ovary, LHCGR-mediated activation of the EGF network and ERK1/2 cascade via Gαs/cAMP
is required for resumption of meiosis, cumulus expansion, and
luteinization, whereas follicular rupture is dependent on both
Gαs and Gαq/11 (6, 16).

reported (25). Clinically, these boys present with precocious
puberty by 3–4 years of age, Leydig cell hyperplasia, and high
circulating levels of testosterone in the context of prepubertal
levels of LH (26–28). Surprisingly, female carriers of activating
mutations are normal. The mutations are limited to exon 11 and
clustered in transmembrane helix 6 and the third intracellular
loop with aspartic acid at position 578 most commonly mutated
to glycine (D578G) (22, 28). This mutation is found in about 62%
of all FMPP cases and 29% of all sporadic cases of male-limited
precocious puberty (29). Only one activating somatic mutation
(D578H) has been identified so far in boys with precocious
puberty and Leydig cell adenomas (30–32) and this mutation has
not been identified in boys with FMPP.
In contrast to the large number of activating and inactivating
mutations in LHCGR, no germ line mutations in the common
α-subunit or hCGβ subunits and no gain-of-function mutations
in LHβ have been identified. Only three inactivating mutations in
LHβ resulting in complete loss of bioactive LH have been reported
in four men and one woman (33–35). In all cases, the males were
normally masculinized at birth but later presented with delayed
or lack of spontaneous puberty, hypogonadism, low testosterone
levels, and infertility. Testicular biopsy revealed absence of complete spermatogenesis and mature Leydig cells (33, 34). This suggests that LH is not required for male sexual differentiation. Fetal
testosterone production begins autonomously and then becomes
dependent on maternal hCG activation of LHCGR. Postnatal
testicular development and function is, however, dependent on
pituitary LH. Treatment with exogenous LH and hCG resulted in
an increase in testosterone, indicating that receptor function was
normal (33). The single female patient showed normal pubertal
development but presented with secondary amenorrhea and
infertility (35). The normal pubertal development is similar to
that seen in women with a homozygous inactivating mutation
in the LHCGR gene (36–39). A fourth mutation resulting in a
deletion of amino acid residues 10–12 of LHβ was reported in
a man and his sister (40). In spite of undetectable levels of LH
and low serum and intratesticular testosterone, the man had
complete spermatogenesis and normal sperm count. The low
residual activity of the mutant LH detected in vitro was apparently
sufficient for normal spermatogenesis. The single female patient
underwent normal puberty, but developed secondary amenorrhea and infertility (35).

Naturally Occurring Mutations in LHCGR
and LHB Genes
The large number of naturally occurring mutations and polymorphisms in the LHCGR gene that result in disorders of sexual
development and reproductive function (4, 17) highlights the
critical role of this receptor in reproduction. Mutations are
inactivating, resulting in loss of receptor function, or activating
resulting in constitutive activation of the receptor. These mutations have been particularly useful in elucidating the molecular
mechanisms of LHCGR activation. Inactivating mutations are
present in all domains of the receptor and may be missense mutations, insertions, deletions, and nonsense mutations. As a result,
there may be partial inactivation or complete loss of receptor
function caused by premature truncation of the receptor protein
or failure to traffic to the cell surface (18). The mutations are
recessive (19) and patients are either homozygous or compound
heterozygous carriers. In males, inactivating mutations result in
failure of testicular Leydig cell differentiation, resulting in the
disorder called Leydig cell hypoplasia (LCH). Two types of Leydig
cell hypoplasia are identified. The severe form is caused by mutations that result in loss of receptor protein, failure of receptor to
traffic to cell surface, or failure to transduce a signal. This results
in 46,XY male pseudohermaphroditism with female external
genitalia, undescended testes, low testosterone, and high LH
levels. The milder form, caused by mutations that allow partial
LHR function, results in micropenis and hypospadia (4, 17, 20).
Testicular histology showed hyalinized basement membrane in
the seminiferous tubules with Sertoli cells but few or no germ cells
(4). Females with inactivating mutations exhibit amenorrhea and
infertility, but normal feminization at puberty indicating that LH
is not essential for pubertal development. Activating mutations
resulting in single amino acid replacements in LHCGR were the
first to be described in patients with familial male-limited precocious puberty (FMPP) (21, 22). This is a rare disorder affecting
upto 9/million (Orphanet/NIH, Office of Rare Diseases). In
early studies, before the availability of molecular analyses, this
disorder was called familial testotoxicosis (23, 24). These mutations are heterozygous and inherited in an autosomal dominant
male-limited pattern although a few sporadic cases have been
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Genetic Models to Study LHCGR Function
Several mouse models have been developed that model human
reproductive disorders involving LHCGR signaling. They include
knockout models of LH and LHCGR to mimic the inactivating
LHβ and LHCGR mutations (41–43) and knockin mice expressing a constitutively active mutant LHCGR (44, 45) to mimic the
activating LHCGR mutations. In addition, several transgenic
models of enhanced LH/hCG action have been generated. They
include mice expressing the LHβ-CGβ carboxyl terminal peptide
(CTP) fusion protein under the control of the bovine common α
subunit promoter (46), mice expressing hCG under the control
of the ubiquitin C (47, 48) or metallothionein promoter (49),
and mice expressing a yoked hCG–LHCGR fusion protein and
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D556H rat LHCGR under the control of the inhibin α subunit
promoter (50).

reduced testis size, poorly developed accessory sex glands, and
micropenis. Testosterone levels were dramatically reduced while
levels of both serum LH and FSH were increased. The testis had
dramatically reduced Leydig cell numbers and spermatogenesis
was arrested in the round spermatid stage (41, 42). The slightly
elevated FSH levels in the LuRKO mice apparently stimulated
spermatogenesis to the round spermatid stage. Further analysis
revealed that the testicular histology of the LuRKO mice was
similar to wild type (WT) mice until about 3 weeks of age. After
3 weeks, the growth rate of the testis was dramatically decreased
(52) and the interstitium lacked adult-type Leydig cells. Leydig
cell-specific and steroidogenic enzyme genes showed similar
level of expression in the neonatal WT and LuRKO mice but the
LuRKO did not show the pubertal increase seen in WT mice.
Testicular testosterone levels were similar between the genotypes
at birth. Expression of the fetal Leydig cell marker Tsp2 was similar
between the genotypes but the adult Leydig cell markers, Hsd3b6
and Hsd17b3, were downregulated at postpubertal ages. Together,
these data suggested that testosterone production by fetal Leydig
cells and initial differentiation of the adult Leydig cell population
are not dependent on LHCGR action. However, differentiation
to the mature Leydig cells with steroidogenic potential requires
LHCGR signaling.
Testosterone replacement therapy at puberty restored full
spermatogenesis and testicular descent, but failed to restore adulttype Leydig cells (53, 54), indicating that androgen-independent
actions of LH are required for adult Leydig cell differentiation.
However, the fertility of the mice could not be completely restored
(54, 55). The subfertile phenotype was determined to be due to
reduced epididymal sperm counts and low ejaculatory frequency.
Additionally, inflammation in the prostate and vas deferens was
observed (54). Interestingly, additional studies by Zhang et al.
(56) reveal that complete spermatogenesis with the appearance
of elongated spermatids can be observed in the LuRKO mice
at 12 months of age although intratesticular testosterone levels
remained suppressed and similar to the levels in 2-month-old
mice. This result suggested that the low level of constitutively
produced intratesticular testosterone was sufficient for differentiation of round to elongated spermatids.

LHβ Knockout Mice
Phenotype of Male Mice

LHβ knockout mice were generated by deleting the coding
sequence of the Lhb gene (43). Heterozygous mice were fertile
and homozyous male and female mice were infertile. Serum
levels of LH were undetectable, while serum FSH levels were
normal. Male mice had significantly smaller testes and accessory
glands consistent with reduced levels of serum and testicular
testosterone. Testes contained very few Leydig cells, which were
mostly fetal and immature adult Leydig cells as indicated by
increased levels of serum androstenedione and upregulation of
the fetal Leydig cell marker, thrombospondin. Spermatogenesis
in the mutant mice was arrested at the round spermatid stage,
indicating that LH and/or testosterone are required for the last
step in spermatogenesis. Some Sertoli cell markers (FSHR) and
inhibin α were unchanged in the knockout mice, while others
(anti-mullerian hormone and the inhibin β subunits) were
upregulated, indicating that lack of LHβ caused both somatic
and germ cell defects. Sexual differentiation and fetal gonadal
development was normal in the knockout mice, indicating that
pituitary LH is not required for fetal testosterone production
and gonadal development. A similar result was seen in mice
lacking the common alpha subunit (α-GSU) for gonadotropin
hormones (51).

Phenotype of Female Mice

Female KO mice were also infertile with abnormal estrous cycles.
Serum estradiol and progesterone were greatly reduced. Primary
and secondary follicles were present in the ovary, but healthy
antral, preovulatory, and corpora lutea (CL) were absent. Antral
follicles contained degenerating oocytes. However, the theca cell
layer appeared normal, indicating that the differentiation of this
layer was independent of LH signaling. Expression of steroidogenic enzyme genes was reduced in both sexes consistent with the
reduction in steroid hormone levels. Treatment of the knockout
mice with hCG rescued the phenotype in both male and female
mice, indicating that receptor responsiveness was normal.

Phenotype of Female Mice

Female KO mice were phenotypically normal at birth, which is
not surprising since female sexual differentiation is independent of ovarian function and ovarian LHCGR expression begins
after birth (57, 58). The age of vaginal opening was delayed in
the KO mice and they did not exhibit normal estrous cyclicity.
The uterus was atrophic with a thinning of all layers and lack of
endometrial glands. Serum levels of estradiol and progesterone
were suppressed but not absent (41). Estradiol and progesterone
replacement therapy of 4-week-old KO mice for a period of
3 weeks stimulated vaginal growth and increased uterine size
(55). However, the number of endometrial glands remained low
and fertility was not restored. The ovaries were greatly reduced
in size and ovaries contained preantral and antral follicles but
no preovulatory follicles or CL (41, 42). This indicates that both
ovulation and the maturation of antral to preovulatory follicles
require LH action. The requirement of LHCGR action for follicle

LHCGR Knockout Mice (LuRKO)

Two groups independently reported the development of the
LHCGR knockout mice by deleting part of the promoter region
and exon 1 (41) or exon 11 encoding the transmembrane and
intracellular domain of the receptor (42). Both models showed
a complete loss of functional receptor resulting in infertility in
both sexes. The reproductive phenotypes described by the two
groups were similar.

Phenotype of Male Mice

Sexual differentiation was normal, demonstrating again that,
unlike in humans, fetal testosterone production required for
masculinization is gonadotropin independent in mice, as previously shown with the LHβ and the common alpha subunit
(αGSU) knockout models (43, 51). The mice were phenotypically
normal at birth. Postnatally, the mice exhibited cryptorchidism,

Frontiers in Endocrinology | www.frontiersin.org

3

September 2015 | Volume 6 | Article 152

Narayan

Mouse models of LHCGR function

maturation beyond the antral stage was novel and was further
investigated in the LuRKO mice (59). This study showed that progression of folliculogenesis beyond the antral stage and induction
of ovulation could not be achieved by hCG or recombinant FSH
in the absence of LHCGR.

Knockin Mice Expressing the Constitutively
Active Mutant D582G LHCGR (KiLHRD582G)

We have recently generated mice expressing a constitutively
active Asp582Gly (D582G) mutant in the mouse LHCGR (44).
The mice are heterozygous with one WT allele replaced by the
mutant allele as seen in patients with FMPP. Expression from
both WT and mutant alleles could be detected in the testis. This
mutation is analogous to the most prevalent Asp578G mutation in humans with FMPP. When tested in cell culture, the
mouse D582G LHCGR showed a similar binding affinity as WT
LHCGR. However, the basal level of cAMP was 23-fold higher
in cells expressing the mutant receptor compared to WT. These
levels are much higher than the three- to fourfold increase in
basal cAMP seen with the human LHCGR (22, 60), and similar
to that obtained with the D578H mutation found in Leydig cell
adenomas (30).

Phenotype of Male Mice

KiLHRD582G mice exhibited precocious puberty as shown by the
advancement of balanopreputial separation and the early detection of mouse urinary proteins in the urine by 15 days compared
to 22 days for WT mice (44). Both are androgen-dependent events
and indicators of puberty in mice (61, 62). Testosterone levels
were elevated as early as 7 days of age while gonadotropin levels
were suppressed. The high testosterone levels resulted in enlarged
seminal vesicles and prostate but not in significantly higher body
weights. Several of the Leydig cell-specific genes involved in the
steroidogenic pathway, including Lhcgr were upregulated. In
spite of the precocious puberty, no advancement in the timing
of spermatogenesis was seen. Spermatogenesis and Sertoli cell
development and function appeared unaffected although testis
size was decreased in the KiLHRD582G mice presumably due to
the suppressed FSH levels. Significantly, Leydig cell hyperplasia
was detected as early as 7 days (Figure 1). The hyperplasia was
patchy with a higher prevalence around the periphery of the testis.
Precocious maturation of adult Leydig cells occurred in the mutant
mice leading to the hyperplasia. The severity of the hyperplasia
appeared to increase in the older animals (Figure 1). Interestingly,
the KiLHRD582G mice became progressively infertile and were
unable to produce litter after an average age of 5–6 months. This
was not due to a defect in spermatogenesis as the number of total
and motile sperm from the cauda epididymis of 6-month-old
KiLHRD582G mice was not different from the WT mice.

FIGURE 1 | Leydig cell hyperplasia in KiLHRD582G mice. Representative
photomicrographs of PASH stained testis sections of WT and KiLHRD582G
from 7 days to 24 weeks of age. At least three animals per age and genotype
were examined. The Leydig cell interstitium is marked by the dashed lines
in sections from the 7-day-old mice. Sections of testis from two 24-week-old
KiLHRD582G mice shows variation in the severity of the Leydig cell hyperplasia.
Bar = 100 μm. From McGee and Narayan (44).

mice compared to WT mice. Consequently, gonadotropin levels
were suppressed. The ovaries and uterus of the KiLHRD582G
mice were enlarged and large cysts were apparent in the gross
morphology of the ovaries. The ovarian histology was normal
in the 2-week-old KiLHRD582G mice. However, degenerating follicles and hemorrhagic cysts were observed starting at 3 weeks
of age (Figure 2). Follicles did not progress beyond the preantral
stage likely due to lack of FSH stimulation. CL were not present
indicating anovulation. Extensive stromal cell hypertrophy
and hyperplasia with luteinization was apparent. In 6-monthold mice, granulosa cell tumors were evident in 50% of the
KiLHRD582G mice. Interestingly, the anovulatory phenotype could

Phenotype of Female Mice

Female KiLHRD582G mice exhibited precocious puberty and the
age of vaginal opening was advanced by 2 weeks compared to
WT mice (45). Mutant mice demonstrated irregular estrous
cyclicity and were infertile. A temporal study from 2 to 24 weeks
of age demonstrated elevated levels of androstenedione, testosterone, estradiol, and progesterone in the serum of KiLHRD582G
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LHβ Overexpressing Transgenic Mice

Transgenic mice expressing a chimeric protein (bLHβ-CTP) consisting of the bovine LHβ subunit fused in frame to the C-terminal
peptide of hCGβ subunit driven by the pituitary-specific bovine
glycoprotein α-subunit (α-GSU) promoter was first reported by
Risma et al. (46). The addition of the CTP increased the circulatory
half-life of LH resulting in constitutive high levels (5- to 10-fold)
in the female but not male mice. Preliminary observations with
the male mice showed reduced fertility and smaller testis in spite
of normal hormone levels and the mice were not characterized
further. Female LHβCTP mice presented with precocious puberty,
elevated levels of testosterone, and estradiol and infertility due to
anovulation (64). The predominant ovarian phenotype was the
presence of hemorrhagic cysts with widespread luteinization of
the interstitial tissue. Accelerated depletion of primordial follicles
was also observed (65). Although anovulation could be reversed by
treatment with exogenous gonadotropins, pregnancy could not be
maintained due to defects in uterine receptivity and mid-gestation
pregnancy failure (66). Additional ovarian defects included granulosa cell tumors by 5 months of age only in the genetic background
of CF-1 mice (67). In a hybrid background, the phenotype
resembled the luteoma of pregnancy and it was shown that three
genes likely control the different phenotypes (67). In addition to
the ovarian tumors, the LHβCTP mice also developed mammary
gland tumors (68). An interesting non-reproductive phenotype
resulting from the elevated LH in the LHβCTP mice is adrenal
hyperplasia and induction of LHCGR expression and activity in the
adrenal gland. As a result, corticosterone production is stimulated
(69). This phenotype was dependent on the dysfunctional ovaries
of the transgenic mice as gonadectomy abolished the adrenocortical hyperfunction. LHβCTP mice also have elevated levels of
prolactin caused by the enhanced estrogen synthesis (69). It has
been suggested that prolactin synergizes with LH in the induction of LHCGR expression in the adrenal glands. Additionally,
LHβCTP female mice are obese (70). Obesity was associated with
hyperphagia, increased intra-abdominal fat, increased levels of
serum leptin and insulin, and reduced thermogenic activity of
brown adipose tissue. The elevated androgens and corticosterone
most likely contribute to the obesity seen in the LHβCTP females
as ovariectomy normalized corticosterone levels and reversed the
obesity and hyperphagia (70). Transgenic females also developed
renal abnormalities, including enlarged bladders, dilated ureters,
and hydronephrosis presumably due to the elevated steroids (46).

FIGURE 2 | Ovarian pathology in KiLHRD582G mice. Representative
photomicrographs of H&E stained ovary sections of WT and KiLHRD582G mice.
At least three animals per age and genotype were examined. Higher
magnification of the boxed areas in sections of KiLHRD582G mice at 4, 6, 12,
and 24 weeks are shown in the last column. C, hemorrhagic cyst; GCT,
granulosa cell tumor; AF, atretic follicle. Arrow indicates tubulostromal
hyperplasia. Scale bars represent 100 μm. From Hai et al. (45).

not be rescued by superovulation with pregnant mare serum
gonadotropin (PMSG) and hCG. Although preovulatory
follicles with oocytes could be detected in the ovaries of the
KiLHRD582G mice, they did not rupture to form CL. This result
suggests that neither the WT or D582G mutant LHCGR is
able to respond to exogenous gonadotropins. LH-dependent
induction of Gαs/cAMP is required for the activation of
the EGF network and the ERK1/2 cascade responsible for
oocyte maturation and cumulus expansion while LH activation of Gαq/11 and Gαs is required for ovulation (6, 16).
Coexpression of a constitutively active hLHR (L457R) that
was unresponsive to additional hormone stimulation, with
the WT LHR in cell culture, caused an attenuation of the
hCG/Gαs stimulated cAMP production by WT LHCGR (63).
This attenuation was not due to a decrease in the cell surface
expression of the WT receptor, but due to the activation
of phosphodiesterase 4D3 resulting in decreased levels of
cAMP. Perhaps a similar mechanism occurs in vivo in the
granulosa cells of the KiLHRD582G mice to inhibit ovulation.
The body weights of KiLHRD582G mice were higher than that
of WT mice. However, there were no changes in body fat
composition or insulin resistance as seen in experimentally
induced hyperandrogenic rodent models of polycystic ovarian syndrome (PCOS).
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hCG Overexpressing Mice

Additional models of enhanced LH/hCG action were indepen
dently developed by two groups. Supraphysiological levels of hCG
were expressed using the human ubiquitin C promoter or the mouse
metallothionein-1 (MT-1) promoter (47–49). Transgenic mice
expressing only the hCGβ subunit or both the common α subunit
and hCGβ from multiple tissues were examined in both sexes.

Phenotype of Male Mice

In male mice expressing only the hCGβ subunit (hCGβ+) under
the human ubiquitin C promoter, circulating levels of dimeric
hCG were detected, indicating that the hCGβ subunit associated
with the endogenously produced α subunit in the pituitary (48).
5
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However, dimeric hCG levels were only 3-4 fold higher than WT
mice because the amount of endogenous α−GSU produced by the
pituitary is rate-limiting. These mice were fertile and presented
with only a mild reproductive phenotype of smaller testes (48).
By contrast, mice expressing the hCGβ subunit under the mouse
MT-1 promoter were infertile although hCG dimer could not be
detected in the serum of these mice and the testes were morphologically and physiologically normal (49). This was surprising as
individual subunits of hCG are devoid of activity (71).
Mice expressing both subunits (hCGαβ+) under the control
of the ubiquitin C promoter produced extremely high levels of
dimeric hCG with about 2000-fold increase in circulating LH/
hCG bioactivity in male mice (48). Serum and testicular testosterone and progesterone were elevated in spite of down regulation
of receptor expression. Male mice were infertile and vaginal plugs
were not observed when mice were mated with superovulated
females in spite of motile and morphologically normal sperm in
the cauda epididymis. Adult mice at 2–6 months of age showed
smaller testes with normal tubular structure. However, progressive degenerative changes in the seminiferous tubules were
observed. Mice developed focal Leydig cell hyperplasia/hypertrophy but not adenomas. Subsequent studies in prepubertal mice
showed Leydig cell adenomas that were of fetal Leydig cell origin
and disappeared at puberty (72). No sign of precocious puberty
was observed in these young mice in spite of elevated levels of
testosterone. The seminal vesicle and prostate were enlarged. The
distention and sperm accumulation in the distal vas deferens
as well as the dilated urinary bladder and ureters and enlarged
kidneys pointed to a functional uretheral obstruction caused by
the overproduction of secretory fluids or impaired emptying of
the accessory glands. This may be a likely cause of infertility in
these mice. Aggressive behavior of the males toward the females
during mating may also contribute to the infertile phenotype.
Matzuk et al. used the MT-1 promoter to generate transgenic
mice expressing low and high levels of the dimeric hCG (49).
Males with low levels of heterodimer expression showed progressive infertility of unknown etiology. Adult males with high
expression levels had similar reproductive defects as described
above, including reduced testis size, Leydig cell hyperplasia,
enlarged fluid-filled seminal vesicles, elevated testosterone levels,
and infertility. Males were very aggressive toward both transgenic
and non-transgenic males or females.

explain the transient increase in estradiol. Hemorrhagic cysts
and CL were present. Females also developed macroprolactinomas and mammary gland tumors at 9–12 months of age.
Serum prolactin was greatly elevated and may help maintain the
ovarian luteinization and progesterone production. Metastasis
of the mammary tumors to the liver, spleen, and lung was seen
in about 47% of the mice. The mammary gland and pituitary
tumors were dependent of ovarian function and ovariectomy
prevented their development even when hCG levels were high.
Subsequent studies (73) showed that the hCGαβ+ mice with the
2000-fold elevation in bioactive LH/hCG develop teratomas.
Mice overexpressing only the hCGβ subunit under the MT-1
promoter were infertile although heterodimer could not be detected
in the serum (49). These mice also had ovarian defects, including
block in folliculogenesis and cysts. Mice with low levels of hCG
dimer became progressively infertile. Mice expressing high levels
of hCG dimer had elevated estradiol levels and developed enlarged
cystic and hemorrhagic ovaries with stromal cell proliferation and
enlarged thecal cell layers. Degenerating kidneys were also evident.
These mice did not develop mammary gland or pituitary tumors.

Yoked Hormone Receptor and Rat D556H
LHCGR Transgenic Mice

Transgenic mice expressing a yoked hormone receptor (YHR+)
genetically engineered by covalently linking hCG to LHCGR
was generated to create a model for constitutively active LHCGR
mutations. In cell culture, YHR exhibited an increase in the
basal level of both cAMP and inositol phosphate similar to that
seen with constitutively active mutants (50, 74). The transgene
was expressed under the control of the gonadal-specific inhibin
α-subunit promoter and male mice were fertile (75). Serum and
testicular testosterone levels were elevated in YHR+ mice at prepubertal ages of 3 and 5 weeks, but not at 8 and 12 weeks of age.
Consistent with the increased testosterone was the increase in
seminal vesicle weights. However, there was no evidence of precocious puberty. Serum levels of LH and FSH were decreased due to
elevated testosterone. Testis size was decreased at all ages in YHR+
mice and histological analysis showed a significant decrease in
the cross-sectional area of the tubules. Spermatogenesis was not
initiated earlier and Leydig cell hyperplasia, as seen in patients
with constitutively active LHCGR, was also not observed. Further
characterization of the male phenotype showed a reduction in
the number of Leydig cells in YHR+ mice accompanied by a
reduction in the expression of several Leydig cell specific genes
(76). The difference in the phenotype of the YHR+ mice from
humans with activating LHCGR mutations is likely because the
inhibin α-subunit promoter did not faithfully mimic the spatial
and temporal expression of LHCGR.
Female YHR+ mice exhibited precocious puberty and were
subfertile. Increased levels of estradiol and progesterone were
observed at 5 weeks of age. However, the hormonal changes
were no longer apparent in adult mice. Increased folliculogenesis
and CL were observed in 5-week-old mice and interstitial cell
hypertrophy, degenerating follicles, and follicular cysts were
observed in adult mice.
Transgenic mice expressing the rat D556H LHCGR under the
control of the inhibin α-subunit promoter was also generated

Phenotype of Female Mice

In contrast to male mice, female transgenic hCGβ+ mice using
the ubiquitin C promoter associated with the endogenously
expressed mouse α-subunit to produce a 40-fold increase in
bioactive LH/hCG compared to WT females (47). Although
female hCGαβ+ mice expressing both subunits as transgenes
produced a 2000-fold elevation in bioactive LH/hCG, the
phenotype of the hCGβ+ and hCGαβ+ mice were similar. Mice
presented with precocious puberty, disrupted estrous cycles,
and infertility. Adult mice were obese due to abdominal fat
accumulation. Transiently elevated estradiol and persistent
elevation of testosterone and progesterone were observed in
the transgenic mice. The ovaries were significantly enlarged
with massive luteinization, resembling luteomas, which may
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inactivating mutations in the LHB gene result in single amino acid,
changes they cause result complete loss of bioactivity similar to
the deletion of the Lhb gene in the mouse. The phenotype of the
homozygous LHβ knockout male and female mice closely mimics
that of humans with the inactivating LHβ mutations (Table 1).
In males, sexual differentiation is normal in humans and mice.
However, in humans, testosterone required for masculinization
in utero is dependent on placental hCG stimulating LHCGR while
in mice it is independent of LH action. LH is critical postnatally and
both humans and mice show hypogonadism, low testosterone levels,
arrest of spermatogenesis, Leydig cell hypoplasia, and infertility.
Female LHβ knockout mice displayed several characteristics
similar to the single female patient with LHβ inactivating mutation identified thus far. Folliculogenesis was arrested at the antral

(50). This mutation corresponds to the somatic D578H mutation
found in Leydig cell adenomas (30–32). Unfortunately, male and
female mice expressing the transgene were infertile which prevented their further characterization. Preliminary analysis of two
infertile founder male mice did not show testicular adenomas.

Comparison of the Mouse Models with
Human Reproductive Pathologies of
LHCGR Function
Inactivating Mutations and Knockout Models

The mouse models of inactivation of LHCGR function have verified existing knowledge, but more importantly have provided new
information on the function of LH. Although the homozygous

TABLE 1 | Summary of genetic models for the study of LHCGR function.
Gene (mutation/
mouse model)

Major human phenotypes

Major mouse phenotypes

Reference

A. COMPARISON OF HUMAN AND MOUSE PHENOTYPES FOR INACTIVATING AND ACTIVATING MUTATIONS IN LH AND LHCGR
LHB (inactivating/
knockout)

LHCGR (inactivating/
knockout)

LHCGR (activating/
knockin)

Construct

Male: infertility, delayed puberty, hypogonadism, Leydig cell
hypoplasia, spermatogenic arrest, normal sexual differentiation

Male: infertility, hypogonadism, Leydig cell hypoplasia,
spermatogenesis arrested at round spermatid stage, normal
sexual differentiation

(43)

Female: normal pubertal development, normal uterus,
folliculogenesis blocked at antral stage, secondary
amenorrhea, infertility

Female: hypogonadal, folliculogenesis blocked at antral stage,
hypoplastic uterus, infertility

Male: micropenis, hypospadia, pseudohermaphroditism,
Leydig cell hypoplasia, germ cell defects

(41, 42)

Female: normal pubertal development, amenorrhea,
folliculogenesis blocked at antral stage, infertility

Male: infertility, Leydig cell hypoplasia, underdeveloped sex
organs, spermatogenesis arrested at round spermatid stage,
normal sexual differentiation
Female: delayed puberty, underdeveloped accessory glands,
follicles arrested at antral stage, infertility

Male: precocious puberty, Leydig cell hyperplasia,
high testosterone

Male: precocious puberty, Leydig cell hyperplasia, high
testosterone, progressive infertility

(44, 45)

Female: normal

Female: precocious puberty, cystic hemorrhagic ovaries
with stromal cell hyperplasia with luteinization, granulosa cell
tumors, infertility

Major phenotypes

Reference

B. TRANSGENIC MOUSE MODELS OF ENHANCED LH/hCG ACTION
α-GSU promoter/
bLHβ-CTP

Males: subfertility, smaller testis

Ubiquitin C promoter/
hCGβ

Males: no phenotype

Ubiquitin C promoter/
hCGαβ

Males: infertility, adult Leydig cell hyperplasia, fetal Leydig cell
adenomas, urethral obstruction, and kidney defects

(46, 66, 67)

Females: precocious puberty, infertility, polycystic ovaries,
stromal cell luteinization, granulosa cell tumors, mammary
gland tumors, hydronephrosis
(47, 48)

Females: precocious puberty, infertility, luteinized cystic
ovaries, prolactinomas, mammary gland tumors
(48, 73)

Females: infertility, ovarian teratomas
MT-1 promoter/hCGβ

Males: infertility

(49)

Females: infertility, cystic, and hemorrhagic ovaries
MT-1 promoter/hCGαβ Males: infertility, Leydig cell hyperplasia

(49)

Females: infertility, cystic, and hemorrhagic ovaries,
degenerating kidneys
Inhibin α-subunit
promoter/YHR

Males: fertile, elevated testosterone with smaller testis, and
Leydig cell hypoplasia

(75)

Females: subfertile, precocious puberty, interstitial cell
hypertrophy
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stage resulting in infertility. Surprisingly, this patient had normal
puberty, with normal sized ovaries and breast and uterine development. Presumably, the low level of estradiol was sufficient for
normal breast and uterine development (35).
Inactivating mutations in LHCGR in human males have a
more severe phenotype, resulting from abnormal sexual differentiation, that those in LHβ emphasizing the importance of
LHCGR signaling in sexual development and postnatal pubertal
development. By contrast, the LuRKO mouse demonstrates that
LHCGR signaling is not essential for mouse sexual differentiation, highlighting a major species difference. LHCGR activation
is, however, important for postnatal development in both species.
The phenotypes of the LHβ and LHCGR knockout male mice are
very similar. Spermatogenic arrest at the round spermatid stage
in both models indicates that FSH alone is not sufficient for full
spermatogenesis and that testosterone produced by LH signaling
is required for postmeiotic germ cell maturation. A novel observation that resulted from studies on the LHCGR knockout mice was
that at 12 months of age, qualitatively complete spermatogenesis
was possible in the absence of LH stimulated high testosterone
production (56). This process, however, requires a long priming
period. From a clinical standpoint, this finding may explain why
men treated with testosterone for contraceptive purposes are not
azoospermic (56).
Women with inactivating LHCGR and LHβ mutations have
normal pubertal development, indicating that LH signaling is not
essential for puberty in women. This process is more dependent
on FSH signaling as demonstrated by lack of pubertal development in women with inactivating mutations in the FSHβ or
FSHR (77). LH signaling is, however, required in the mouse where
absence of LHCGR delays pubertal development (Table 1). There
is a remarkable similarity in the ovarian phenotype of women
with inactivating LHβ and LHCGR mutations, LHβ knockout
and LuRKO mice showing a block in folliculogenesis at the antral
stage. The studies from these mouse models clearly showed for
the first time that, in addition to its well-known role in ovulation,
LH is also required for the final stage of follicular maturation
before ovulation. Studies with the LuRKO mice (59) also clarified
that ovulation could not be induced by FSH in the absence of
functional LHCGR as has been previously suggested (78, 79).

expression of the androgen receptor in Sertoli cells can accelerate spermatogenic development (80). Two new findings form the
mouse model, not previously reported or confirmed in FMPP
cases, are that the hyperplasia is not uniform throughout the
testis and that it results from the precocious development of
adult Leydig cells. The progressive infertility and hyperplasia
seen in the KiLHRD582G mice suggest that FMPP patients may
be susceptible to infertility and perhaps tumor development
later in life. There is only one report of a FMPP patient with the
D578G mutation who was diagnosed with nodular Leydig cell
hyperplasia (81), primarily due to lack of long-term follow-up of
FMPP patients past puberty.
The phenotype of female KiLHRD582G mice (45) is distinctly
different from women with activating mutations who are normal
(82–84). Mice undergo precocious puberty and are infertile with
significant ovarian pathology of hemorrhagic cysts, stromal
cell hyperplasia, and granulosa cell tumors. The reason for this
discrepancy is unclear. The low level of LHCGR expression in
prepubertal girls, the requirement for the activation of both
LHCGR and FSHR for puberty, and less efficient androgen synthesis in theca cells compared to Leydig cells (4, 82). A higher
magnitude of LHCGR activation may be required for development of ovarian pathology. In this context, the mouse LHCGR
has a higher level of constitutive activation than the human
receptor and the phenotype of the female KiLHRD582G mice is
similar to transgenic models of LH and hCG overexpression. A
novel finding from the study of KiLHRD582G mice is the dominant
negative effect of the mutant receptor on the function of the WT
receptor. The lack of rescue of the anovulatory phenotype by
the administration of PMSG and hCG indicated that D582G
LHCGR inhibits signaling of the WT receptor and is the first
report of such an effect in vivo.
In general, the knockout and knockin mouse models are
close phenocopies of the human disorders; however, species
differences in LHCGR function clearly exist. Although these
differences provide useful knowledge on LHCGR physiology,
they should be considered when the mice are used as models of
human diseases.

Transgenic Models of Enhanced LH/hCG Action

Activating mutations in LH or hCG have not been identified.
However, there are physiological and pathological states when
these hormone levels are elevated. hCG is produced in high
amounts in the first trimester of pregnancy and in gestational
trophoblastic disease (1). In men and women, hCGβ, hyperglycosylated hCGβ, and occasionally hCG dimer are secreted
from a variety of tumors (1). Gonadotroph adenomas induce
high gonadotropin levels and hypersecretion of LH is observed
in pathological conditions such as PCOS. Chronic elevation of
gonadotropins occurs in menopause and this is proposed as risk
factor for ovarian cancer (85).
A comparison of the phenotypes of the overexpressing LH/
hCG mice is shown in Table 1. The LHβ-CTP model was the
first overexpressing model described. Hormone levels were not
elevated in male mice because the α-GSU promoter is inefficient
in the male. Overexpression of dimer hCG driven by either the
ubiquitin C or MT promoter resulted in similar male phenotypes

Activating Mutations and Knockin Models

The most common mutation in FMPP is the D578G mutation
in transmembrane helix 6. In the mouse model (KiLHRD582G)
generated in our laboratory, the corresponding D582G mutation
was introduced into the WT Lhcgr gene (44). The male mouse is
a good phenocopy of men with constitutively activating LHCGR
mutations as shown by the development of precocious puberty,
Leydig cell hyperplasia and high testosterone (Table 1). A major
difference between the mouse model and FMPP patients is that
spermatogenesis is not advanced in the KiLHRD582G mouse.
Presumably, the seminiferous cycle of 35 days is at a minimum
in mice and cannot be shortened further even with premature
testosterone production. Furthermore, spermatogenic development requires the expression of the androgen receptor in Sertoli
cells and significant levels are not detected till around postnatal
day 15 in mice (80). It has been demonstrated that premature
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of infertility and Leydig cell hyperplasia with high testosterone
levels. Aggressive behavior of the males toward the females was
observed in both hCG models and this may contribute in part
to the infertile phenotype. The infertility in the ubiquitin C
promoter-driven hCG mice was not due to defects in sperm but
possibly due to the urethral obstruction (48).
The pathological changes seen in the female LHβ-CTP and
hCG overexpressing mice were similar with precocious puberty
and infertility. Significant pathology was seen in all models, with
cystic, hemorrhagic, and luteinized ovaries. Granulosa cell tumors
were seen in the LHβ-CTP mice, but ubiquitin C promoter-hCG
mice had ovarian luteomas and teratomas and no tumors were
found in the MT-hCG mice. Both LHβ-CTP and ubiquitin C
promoter-hCG mice develop mammary gland tumors, but the
latter also develop prolactinomas in older mice. This indicates that
chronic high levels of gonadotropins promote tumor formation
in gonadal and non-gonadal tissues. The pituitary and mammary
gland tumors are secondary effects of aberrant gonadal function.
The inhibin α-subunit promoter-YHR mice did not exhibit the
robust changes seen in the overexpressing mice in either males
or females.
The LH/hCG overexpressing models and the inhibin α-subunit
promoter-YHR mice were expected to mimic the activating
LHCGR mutations by precocious activation of the receptor.
Comparison of the male KiLHRD582G mice with the transgenic
mouse models of LH/hCG overexpression showed similar phenotypes of Leydig cell hyperplasia and high testosterone. Similar
to the ubiquitin C promoter-hCG mice, the progressive infertility
in the KiLHRD582G mice was not due to sperm defects. However,
there were distinct differences as well. The overexpressing models
did not exhibit precocious puberty and Leydig cell adenomas in
the ubiquitin promoter-hCG mice were of fetal origin rather than
from adult Leydig cells as seen in the KiLHRD582G mice. The inhibin α-subunit promoter-YHR mice did not exhibit phenotypes
similar to either the KiLHRD582G mice or LH/hCG overexpressing
mice except for the increase in testosterone. Presumably, the
promoter used was regulated differently from the endogenous
LHCGR.
The reproductive (precocious puberty, infertility) and ovarian phenotypes (cystic, hemorrhagic ovaries, interstitial cell
hypertrophy with luteinization, granulosa cell tumors) of the
KiLHRD582G mice are similar to the LH/hCG overexpressing
mice. The luteomas, teratomas (47), and enlarged thecal cell
layer are specific to the hCG overexpressing mice (49, 73).
The extra-gonadal phenotypes of pituitary and mammary
gland tumors are not also seen in the KiLHRD582G mice. The
obese phenotype seen in the LHβ-CTP and ubiquitin-hCG
overexpressing mice is not evident in the KiLHRD582G mice. In
contrast to the KiLHRD582G mice, the anovulatory phenotype of
the LHβ-CTP could be rescued by exogenous gonadotropins
(66), further confirming an inhibition of WT LHCGR function in the KiLHRD582G mice. The differences in the phenotypes
between the overexpressing models and KiLHRD582G mice,
particularly the extra-gonadal phenotypes, are likely due to
the high levels of LH/hCG secreted by transgenes that were
expressed ubiquitously under the control of promoters that do
not mimic the spatial or temporal expression of LHCGR. Some
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of the differences between the three overexpressing models
may be the result of different levels of hormone production,
different promoters, and genetic background. However, the
remarkable number of similarities between the models emphasizes the importance of LH/LHCGR action on reproductive
physiology and pathophysiology.

Future Perspectives
Mouse models are now available that can mimic the genetic
alterations in LH and LHCGR and physiological and pathological states of hormone excess. These models have reinforced the
well-established roles of LH and LHCGR but have also uncovered
novel functions. The KiLHRD582G mice can be used to investigate
the long-term reproductive and non-reproductive abnormalities
that result from constitutive LHCGR activity, particularly the
mechanism of the progressive infertility. This information will
be useful in predicting the long-term health of FMPP patients.
This mouse model will be valuable to test new therapeutic agents
that can block constitutive activity and to further determine the
in vivo mechanism of the dominant negative effect of the mutant
receptor on WT receptor function. Based on the phenotypic
changes seen in the models of enhanced LH/hCG action, it
appears that female physiology is more sensitive to changes in
LH-mediated signaling. In particular, these models can be used
to better understand the signaling mechanisms important in the
development of ovarian and extra-gonadal tumors and understand the role of LH in obesity and related metabolic changes.
The models can be helpful in sorting out the controversies and
conflicting data regarding the extra-gonadal actions of LHCGR.
In general, all the described models are amenable to large-scale
gene expression profiling to better understand LHCGR signaling
mechanisms.
An area that has not been explored extensively is the neurological changes associated with LHCGR signaling. Testosterone
is important in brain development and sexual differentiation.
Behavioral studies have shown that FMPP patients are susceptible to attention deficit hyperactivity disorder and a higher
rate of anxiety disorder (86). The KiLHRD582G mice are an ideal
animal model to assess cognitive and behavioral changes associated with FMPP. There is also increasing evidence that elevated
levels of LH can exacerbate age-related cognitive decline in
Alzheimer’s disease (87, 88). LHβ-CTP mice exhibit cognitive
deficits (89). Considering that functional LHCGR is expressed
in the brain (90), it will be of interest to determine if cognitive
and behavioral changes are due to direct LHCGR signaling
in the brain or indirectly due to its activity in gonads. These
mechanisms and the contributions of direct vs. indirect effects
on the brain can be teased out with the mouse models. Clearly,
these mouse models have the potential to uncover novel aspects
of LHCGR signaling.
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